Background: This prespecified subgroup analysis of the FIDELIO-DKD trial aimed to evaluate the efficacy and safety of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes melli
Background: Attainment of therapeutic goals in Type 2 Diabetes Mellitus (T2DM) necessitates the rational use of drugs, given the wide options available and the presence of co-morbid diseases. Objec
Legend: Unadjusted and adjusted hazard ratios (HR) and 95% Confidence Intervals (CI) for end-stage renal disease (ESRD) and death associated with 1 unit (µmol/L) change in homoarginine. (‡) Relative r
Introduction: Dipeptidyl peptidase-4 (DPP4) inhibitors (gliptins) are commonly prescribed for glucose control in patients with advanced chronic kidney disease (CKD) in whom other oral gl
